AU2016204734B2 - Method for generating high-titer Hepatitis E virus stocks and titration assay for Hepatitis E virus - Google Patents

Method for generating high-titer Hepatitis E virus stocks and titration assay for Hepatitis E virus Download PDF

Info

Publication number
AU2016204734B2
AU2016204734B2 AU2016204734A AU2016204734A AU2016204734B2 AU 2016204734 B2 AU2016204734 B2 AU 2016204734B2 AU 2016204734 A AU2016204734 A AU 2016204734A AU 2016204734 A AU2016204734 A AU 2016204734A AU 2016204734 B2 AU2016204734 B2 AU 2016204734B2
Authority
AU
Australia
Prior art keywords
hepatitis
virus
titer
titration assay
generating high
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016204734A
Other languages
English (en)
Other versions
AU2016204734A1 (en
Inventor
Brett Buno
Michael Burdick
Joann Hotta
Terri Journigan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols SA
Original Assignee
Grifols SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols SA filed Critical Grifols SA
Publication of AU2016204734A1 publication Critical patent/AU2016204734A1/en
Application granted granted Critical
Publication of AU2016204734B2 publication Critical patent/AU2016204734B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02Recovery or purification
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/067Hepatocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0693Tumour cells; Cancer cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • C12Q1/706Specific hybridization probes for hepatitis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • C12Q1/706Specific hybridization probes for hepatitis
    • C12Q1/707Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05Adjuvants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/28011Hepeviridae
    • C12N2770/28111Hepevirus, e.g. hepatitis E virus
    • C12N2770/28121Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/28011Hepeviridae
    • C12N2770/28111Hepevirus, e.g. hepatitis E virus
    • C12N2770/28151Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AU2016204734A 2015-07-23 2016-07-08 Method for generating high-titer Hepatitis E virus stocks and titration assay for Hepatitis E virus Active AU2016204734B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562195936P 2015-07-23 2015-07-23
US62/195,936 2015-07-23

Publications (2)

Publication Number Publication Date
AU2016204734A1 AU2016204734A1 (en) 2017-02-09
AU2016204734B2 true AU2016204734B2 (en) 2019-11-21

Family

ID=56409494

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016204734A Active AU2016204734B2 (en) 2015-07-23 2016-07-08 Method for generating high-titer Hepatitis E virus stocks and titration assay for Hepatitis E virus

Country Status (22)

Country Link
US (1) US10208291B2 (enExample)
EP (1) EP3121267B1 (enExample)
JP (1) JP6588397B2 (enExample)
KR (1) KR102154380B1 (enExample)
CN (1) CN106367397B (enExample)
AR (1) AR106015A1 (enExample)
AU (1) AU2016204734B2 (enExample)
BR (1) BR102016016677A2 (enExample)
CA (1) CA2937088C (enExample)
CL (1) CL2016001768A1 (enExample)
ES (1) ES2669021T3 (enExample)
HU (1) HUE036699T2 (enExample)
IL (1) IL246634B (enExample)
MX (1) MX375106B (enExample)
MY (1) MY176204A (enExample)
NZ (1) NZ722213A (enExample)
PL (1) PL3121267T3 (enExample)
PT (1) PT3121267T (enExample)
RU (1) RU2691123C1 (enExample)
SG (1) SG10201605867UA (enExample)
TW (1) TWI666322B (enExample)
UY (1) UY36778A (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102158641B1 (ko) * 2019-03-06 2020-09-22 대한민국 야누스 인산화효소 저해제 및 헥사디메트린 브로마이드를 포함하는 바이러스 배양용 조성물 및 이를 이용한 바이러스 배양 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007046962A2 (en) * 2005-09-02 2007-04-26 The University Of Maryland, Baltimore Cell lines harboring hepatitis virus and methods for using thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506604B2 (en) * 1993-06-11 2003-01-14 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US6217858B1 (en) * 1997-02-11 2001-04-17 Hadasit & Medical Research Services & Development Company, Ltd. Pharmaceutical composition for treating hepatitis B virus (HBV) infection
WO2003001198A1 (en) * 2001-06-21 2003-01-03 Regents Of The University Of California Immortalization of human cells by the ectopic expression of human telomerase reverse transcriptase
AU2009298371A1 (en) * 2008-10-03 2010-04-08 The Rockefeller University New HCV entry factor, Occludin
EP2663328B1 (en) * 2011-01-10 2018-09-19 The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services Infectious hepatitis e virus genotype 3 or 1 recombinants
CA2838749A1 (en) * 2011-06-10 2012-12-13 Bluebird Bio, Inc. Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007046962A2 (en) * 2005-09-02 2007-04-26 The University Of Maryland, Baltimore Cell lines harboring hepatitis virus and methods for using thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. VILA-BRAU ET AL, "Human HMGCS2 Regulates Mitochondrial Fatty Acid Oxidation and FGF21 Expression in HepG2 Cell Line", JOURNAL OF BIOLOGICAL CHEMISTRY, (2011-04-18), vol. 286, no. 23, pages 20423 - 20430 *
GARY CRAMERI ET AL, "Establishment, Immortalisation and Characterisation of Pteropid Bat Cell Lines", PLOS ONE, (2009-12-11), vol. 4, no. 12, doi:10.1371/journal.pone.0008266, page e8266 *

Also Published As

Publication number Publication date
KR20170012140A (ko) 2017-02-02
PL3121267T3 (pl) 2018-07-31
TWI666322B (zh) 2019-07-21
RU2691123C1 (ru) 2019-06-11
MX2016009048A (es) 2017-01-23
CN106367397A (zh) 2017-02-01
PT3121267T (pt) 2018-04-26
AR106015A1 (es) 2017-12-06
TW201704468A (zh) 2017-02-01
IL246634A0 (en) 2016-12-29
EP3121267B1 (en) 2018-03-28
BR102016016677A2 (pt) 2019-02-12
ES2669021T3 (es) 2018-05-23
IL246634B (en) 2020-08-31
JP2017023143A (ja) 2017-02-02
US10208291B2 (en) 2019-02-19
HUE036699T2 (hu) 2018-07-30
MY176204A (en) 2020-07-24
CA2937088A1 (en) 2017-01-23
AU2016204734A1 (en) 2017-02-09
CA2937088C (en) 2022-06-21
JP6588397B2 (ja) 2019-10-09
UY36778A (es) 2016-09-30
CL2016001768A1 (es) 2017-05-12
KR102154380B1 (ko) 2020-09-10
CN106367397B (zh) 2021-07-20
SG10201605867UA (en) 2017-02-27
MX375106B (es) 2025-03-06
US20170022481A1 (en) 2017-01-26
NZ722213A (en) 2019-04-26
EP3121267A1 (en) 2017-01-25

Similar Documents

Publication Publication Date Title
CY1124717T1 (el) Μεθοδοι, kit και συσκευη για επεκταση πληθυσμου κυτταρων
EA201992795A1 (ru) Способ получения эукариотических клеток с отредактированной днк и набор, используемый в этом способе
EA201992001A1 (ru) Композиции и способы повышения экспрессии генов
MX2016016902A (es) Metodos para analizar acidos nucleicos de celulas individuales o poblaciones de celulas.
EP4269577A3 (en) Nucleobase editors and uses thereof
EP4287191A3 (en) Hla-based methods and compositions and uses thereof
WO2015042393A3 (en) Evolved sortases and uses thereof
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
WO2020081149A8 (en) Improved detection of nuclease edited sequences in automated modules and instruments
EP4219744A3 (en) Methods of preparing nucleic acids for sequencing
EP4600650A3 (en) Improved methods and compositions for synthetic biomarkers
BR112017009728A2 (pt) anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
WO2015160895A3 (en) Modified transposases for improved insertion sequence bias and increased dna input tolerance
BR112019016672A8 (pt) Método para gerar progenitores de células t
GB2548740A (en) Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
BR112017016897A2 (pt) cepas fúngicas e métodos de uso
EP4628631A3 (en) Conditional primer extension for single-molecule detection
EP4220158A3 (en) Urine specimen analysis device and urine specimen analysis method
MX2018015213A (es) Secuencia de acido nucleico para detectar la existencia del evento de soya transgenica dbn9004 en una muestra biologica, equipo que contiene la misma y metodo de deteccion para la misma.
EP4316500A3 (en) Bio-production of lentiviral vectors
MX2019011702A (es) Ensayos de inmunogenicidad mejorados.
AU2017248682A1 (en) Method for detecting and/or characterising tumour cells and associated apparatus
WO2014145870A3 (en) Novel compositions, methods and kits for blood typing
CA3077390A1 (en) Methods and compositions for nucleic acid detection
WO2019239218A3 (en) Determination of epigenetic modifications by nanopore sequencing

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)